Connect your AI

NAGE NAGE Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

eXoZymes Inc. Common StockEXOZ

——

Lifevantage CorporationLFVN

——

NuSkin EnterprisesNUS

——

AbbottABT

——

Maravai LifeSciences Holdings, Inc.MRVI

——

ANI PharmaceuticalsANIP

——

Other financials

Income statement

Revenue$31.5M+3.3%

Gross profit$20.0M+3.3%

Operating income$1.6M-67.0%

Net income$6.3M+24.8%

EPS (diluted)$0.07+16.7%

Balance sheet

Cash & equivalents$66.5M+19.7%

Total debt$2.6M-26.9%

Total equity$82.3M+48.8%

Total assets$114.3M+40.6%

Cash flow

Operating cash flow-$1.2M-115%

Valuation

Market cap$254.07M-74.9%

Enterprise value$190.09M-79.7%

P/E13.6×-43.5×

P/S2×-6.8×

Profitability

Gross margin64.3%+1.8pp

Operating margin10%-2.2pp

Net margin14.3%+1.2pp

FCF margin-70.4%—

Returns & leverage

Return on equity27.1%-6.4pp

Debt / equity0×0.0×

Current ratio4.6×+0.9×

Where this comes from

Reported directly by NAGE in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: NAGE’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about NAGE's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is NAGE's remainder of fiscal year 2024?: NAGE (NAGE) reported remainder of fiscal year 2024 of $957K in Q1 2026.
How has NAGE's remainder of fiscal year 2024 changed year-over-year?: NAGE's remainder of fiscal year 2024 increased by 18.6% year-over-year, from $807K to $957K.